Procter & Gamble Health Limited (PGHL.NS)
INR 5467.25
(0.04%)
INR 5467.25
(0.04%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.94 Billion INR | -27.86% |
| 2022 | 11.01 Billion INR | 23.21% |
| 2021 | 8.93 Billion INR | -9.37% |
| 2020 | 9.86 Billion INR | -16.17% |
| 2019 | 11.76 Billion INR | -33.14% |
| 2018 | 17.59 Billion INR | 77.5% |
| 2017 | 9.91 Billion INR | 12.28% |
| 2016 | 8.82 Billion INR | 12.61% |
| 2015 | 7.83 Billion INR | 10.7% |
| 2014 | 7.08 Billion INR | 9.19% |
| 2013 | 6.48 Billion INR | 9.14% |
| 2012 | 5.94 Billion INR | 18.94% |
| 2011 | 4.99 Billion INR | 16.2% |
| 2010 | 4.29 Billion INR | -24.32% |
| 2009 | 5.68 Billion INR | 1.36% |
| 2008 | 5.6 Billion INR | 14.5% |
| 2007 | 4.89 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 7.94 Billion INR | -27.86% |
| 2023 Q4 | 7.94 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 10.77 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 11.01 Billion INR | 23.21% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 11.01 Billion INR | 0.0% |
| 2022 Q2 | 10.79 Billion INR | 0.0% |
| 2021 Q4 | 8.93 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 8.48 Billion INR | 0.0% |
| 2021 FY | 8.93 Billion INR | -9.37% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q2 | 8.51 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 9.86 Billion INR | 0.0% |
| 2020 FY | 9.86 Billion INR | -16.17% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q4 | 11.75 Billion INR | 0.0% |
| 2019 FY | 11.76 Billion INR | -33.14% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 17.59 Billion INR | 77.5% |
| 2018 Q2 | 17.59 Billion INR | 0.0% |
| 2018 Q4 | 9.73 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 9.91 Billion INR | 12.28% |
| 2017 Q4 | 10.27 Billion INR | 0.0% |
| 2017 Q2 | 9.91 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 9.03 Billion INR | 0.0% |
| 2016 FY | 8.82 Billion INR | 12.61% |
| 2016 Q2 | 8.82 Billion INR | 0.0% |
| 2015 FY | 7.83 Billion INR | 10.7% |
| 2015 Q4 | 8.11 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 7.83 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 7.08 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 7.08 Billion INR | 9.19% |
| 2014 Q4 | 7.62 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 FY | 6.48 Billion INR | 9.14% |
| 2013 Q2 | 6.48 Billion INR | 0.0% |
| 2013 Q4 | 6.85 Billion INR | 0.0% |
| 2012 FY | 5.94 Billion INR | 18.94% |
| 2012 Q2 | 5.94 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q4 | 6.41 Billion INR | 0.0% |
| 2011 FY | 4.99 Billion INR | 16.2% |
| 2011 Q2 | 4.99 Billion INR | 0.0% |
| 2011 Q4 | 10.85 Billion INR | 0.0% |
| 2010 FY | 4.29 Billion INR | -24.32% |
| 2009 FY | 5.68 Billion INR | 1.36% |
| 2008 FY | 5.6 Billion INR | 14.5% |
| 2007 FY | 4.89 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sigachi Industries Limited | 6.94 Billion INR | -14.435% |
| Ind-Swift Limited | 6.54 Billion INR | -21.374% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -3.821% |
| Sakar Healthcare Limited | 3.88 Billion INR | -104.385% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 98.238% |
| Innova Captab Limited | 13.2 Billion INR | 39.861% |
| Divi's Laboratories Limited | 154.7 Billion INR | 94.865% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 26.314% |
| Morepen Laboratories Limited | 12.93 Billion INR | 38.574% |
| Mankind Pharma Limited | 119.63 Billion INR | 93.36% |
| Sequent Scientific Limited | 15.4 Billion INR | 48.431% |
| Wanbury Limited | 3.43 Billion INR | -131.259% |
| Laurus Labs Limited | 83.87 Billion INR | 90.529% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 63.745% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 72.132% |
| Alembic Limited | 23.28 Billion INR | 65.889% |
| Hikal Limited | 24.87 Billion INR | 68.061% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 87.676% |
| Neuland Laboratories Limited | 18.32 Billion INR | 56.653% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 80.112% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 94.468% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 64.607% |
| Themis Medicare Limited | 5.66 Billion INR | -40.243% |
| RPG Life Sciences Limited | 5.12 Billion INR | -54.885% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 97.287% |
| Lupin Limited | 239.97 Billion INR | 96.69% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -116.523% |
| Wockhardt Limited | 76.49 Billion INR | 89.615% |
| Vaishali Pharma Limited | 799.55 Million INR | -893.5% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 69.236% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -265.933% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 93.122% |
| FDC Limited | 24.68 Billion INR | 67.815% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 97.95% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -230.898% |
| Eris Lifesciences Limited | 70.48 Billion INR | 88.731% |
| Venus Remedies Limited | 6.26 Billion INR | -26.727% |
| ZIM Laboratories Limited | 4.46 Billion INR | -77.78% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 34.56% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -681.765% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 70.551% |
| Shilpa Medicare Limited | 30.93 Billion INR | 74.319% |
| Albert David Limited | 4.97 Billion INR | -59.513% |
| Ajanta Pharma Limited | 46.38 Billion INR | 82.874% |
| Hester Biosciences Limited | 6.62 Billion INR | -19.931% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 64.759% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 66.148% |
| Gufic Biosciences Limited | 10.92 Billion INR | 27.292% |
| Windlas Biotech Limited | 6.26 Billion INR | -26.853% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -160.453% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -138.243% |
| Granules India Limited | 55.2 Billion INR | 85.612% |
| Aarti Drugs Limited | 24.32 Billion INR | 67.342% |
| Bal Pharma Limited | 3.2 Billion INR | -147.936% |
| Alkem Laboratories Limited | 155.74 Billion INR | 94.9% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.071% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | -13.433% |
| Medicamen Biotech Limited | 2.94 Billion INR | -169.711% |
| Unichem Laboratories Limited | 31.69 Billion INR | 74.936% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -437.887% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -1587.159% |
| Valiant Laboratories Limited | 3.42 Billion INR | -131.803% |
| Orchid Pharma Limited | 15.53 Billion INR | 48.879% |
| Medico Remedies Limited | 961.95 Million INR | -725.778% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 31.821% |
| Ipca Laboratories Limited | 111.01 Billion INR | 92.844% |
| Brooks Laboratories Limited | 904.45 Million INR | -778.276% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -96.301% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.038% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 94.726% |
| NATCO Pharma Limited | 69.06 Billion INR | 88.498% |
| Suven Life Sciences Limited | 2.84 Billion INR | -178.818% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -345.832% |
| Strides Pharma Science Limited | 58.39 Billion INR | 86.397% |
| Indoco Remedies Limited | 21.44 Billion INR | 62.962% |
| Alpa Laboratories Limited | 1.82 Billion INR | -334.976% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -426.524% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -54.233% |